Siemens Healthineers Balances Diagnostics Savings Against a Steeper Interest Bill
Published on 11/06/2026 at 15:31 | Editorial boerse-global.de
Siemens Healthineers delivered topline growth in its latest annual report, but the harder question for investors is what survives below the operating line. Higher financing costs, a dip in adjusted operating profit and a diagnostics restructuring all now shape the earnings story, with the planned separation from Siemens as the strategic backdrop.
Comparable revenue rose 4.0% in fiscal 2026, and the adjusted EBIT margin came in at 16.2%. Adjusted EBIT reached roughly EUR 3.8 billion, down from EUR 3.86 billion a year earlier — a reminder that more business only strengthens earnings power once costs and margins keep pace.
Fourth-quarter momentum, and the margin question
The final three months offered the clearest read on demand. Comparable revenue growth accelerated to 5.9%, while the adjusted EBIT margin for the quarter stood at 15.9%. In the equipment business, the book-to-bill ratio reached 1.15, an order intake above sales that underpins the growth outlook — provided that demand is served at a profitable level.
Adjusted earnings per share for fiscal 2026 came in at EUR 2.42. Stripping out customs refunds and larger one-offs in the closing quarter, the figure was EUR 2.30.
Should investors sell immediately? Or is it worth buying Siemens Healthineers?
For fiscal 2027, management projects comparable revenue growth of 4–5% and adjusted earnings per share of EUR 2.20–2.40. That range spans a decline to an increase against the cleaned-up base, leaving the expected sales gain to offset the added burdens.
Interest costs take a bigger bite
Net finance expenses are forecast at EUR 400–440 million for fiscal 2027, up from EUR 300 million in fiscal 2026. The step-up argues against an unbridled translation of revenue growth into per-share profit: operating progress must first cover the extra financing burden before it reaches shareholders in full.
Analyst reaction split along the same fault line. Jefferies kept the stock at "Buy" with a EUR 50 target, with analyst Julien Dormois flagging organic growth ahead of expectations and pointing to the recovery in Imaging as the driver. UBS stayed at "Neutral" with a EUR 38 target, citing adjusted EBIT below expectations and possible drag from the diagnostics carve-out. Media reports noted that analysts homed in on adjusted EBIT and margin undershooting forecasts.
Diagnostics targeted for EUR 400 million in savings
Within the diagnostics division, Siemens Healthineers announced additional savings of EUR 400 million. Finance chief Jochen Schmitz said the measures are needed to reach margins in the mid-teens percent range. The savings carry real value for the investment case if they lift operating profitability — their effect on the result is what counts.
Free cash flow of roughly EUR 2.4 billion in fiscal 2026 rounds out the positive side of the ledger, complementing adjusted profit with the cash actually generated. That argument gains weight if the company keeps producing funds reliably through the organizational changes.
Siemens Healthineers at a turning point? This analysis reveals what investors need to know now.
Spin-off vote set for February 2027
The corporate restructuring is taking concrete shape. After the spin-off from Siemens, Siemens Healthineers plans to take the name Healthineers. Both steps are subject to approval. Shareholders of both companies are to vote on the spin-off at their annual general meetings in February 2027, and the renaming also requires the backing of the Siemens Healthineers AGM. Three years are earmarked for the brand transition.
The next hard datapoint is the annual report for fiscal 2026, scheduled for release on November 25, 2026. Investors will then be able to check what additional insight it offers on earnings, cash flow and the restructuring. A more convincing re-rating would require those disclosures to strengthen confidence in operational execution. Should earnings lag expectations, even solid demand would carry less weight — which keeps the margin as the central yardstick for the next investment decision.
Ad
Siemens Healthineers Stock: New Analysis - 6 November
Fresh Siemens Healthineers information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
